CAS: 5819-47-6; Magnesium (S)-2-Carboxylato-5-Oxopyrrolidin-1-Ide

专利信息

专利号:US-12383520-B2
优先权日:2019-05-16
标 题 :Compound and composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder
发明人：DANHIER PHILIPPE; AZZAM PASCALE
权利人:SYNAPHARM IND SYNTHESIS
摘要:This invention pertains to a compound and a composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder.

专利号:EP-3738596-B1
优先权日:2019-05-16
标题:Compound and composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder
发明人：DANHIER PHILIPPE; AZZAM PASCALE
权利人:SYNAPHARM IND SYNTHESIS

专利号:WO-2024217504-A1
优先权日:2023-04-18
标题 :Conjugate, and use thereof and preparation therefor
发明人：SHA WEI; LIU YANG; JIN YANLIN; WANG JING; FANG DOUGLAS; ZHANG HAOLONG
权利人:SHENZHEN VYBIO PHARMACEUTICAL TECH CO LTD
摘要:Disclosed in the present invention are a conjugate, and the use thereof and the preparation therefor. Provided in the present invention is a GalNAc conjugate as represented by formula I. The GalNAc conjugate in the present invention has one or more of the following advantages: the conjugate of the present invention reduces the activity of antigens on the surface of HBV, has no cytotoxicity and good safety, and has a good hepatocyte targeting property, high binding affinity to ASGPR and high drug delivery efficiency; and the conjugate of the present invention has a short synthesis route, and has high synthesis efficiency and is low cost.

专利号:WO-2025098440-A1
优先权日:2023-11-08
标题:Double-stranded sirna for inhibiting pnpla3 expression and conjugate comprising same
发明人：JIN YANLIN; LIU YANG; WANG JING; ZHOU QICHEN; DING ZHAOZHONG; FANG DOUGLAS; SHA WEI
权利人:ZHEJIANG YANGLI PHARMACEUTICAL TECH CO LTD
摘要:A double-stranded siRNA for inhibiting PNPLA3 expression and a conjugate comprising same. The double-stranded siRNA comprises a sense strand and an antisense strand, wherein one or more nucleotide residues in a nucleotide sequence of the sense strand and/or the antisense strand are replaced with r1 represented by formula I: formula (I). The introduction of a non-natural nucleotide monomer into the double-stranded siRNA improves the target selectivity and activity of the siRNA sequence, reducing the off-target risk while maintaining high drug activity. Also provided is a tetravalent GalNAc, making it easier to scale up synthesis and reduce costs.